Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113016627> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W3113016627 endingPage "ii66" @default.
- W3113016627 startingPage "ii66" @default.
- W3113016627 abstract "Abstract Poly (ADP-ribose) polymerase (PARP) inhibition could enhance the efficacy of temozolomide and prolong survival in patients with glioblastoma. The aim of this study was to evaluate the combination of the PARP inhibitor olaparib with temozolomide in the treatment of glioblastoma by evaluating in vitro and in vivo antitumor effects in an experimental glioblastoma model. The authors investigated antitumor effects of olaparib on temozolomide-induced cytotoxicity on O6-methylguanine methyltransferase (MGMT) promotor methylated (U87MG, U251MG) and MGMT promotor unmethylated (T98G) glioblastoma cell lines using in vitro cell viability and apoptosis assay. We found that the combination of olaparib with temozolomide enhanced temozolomide-induced cytotoxicity in all glioblastoma cell lines regardless of the status of MGMT promotor methylation. For in vivo studies, nude mice bearing orthotopically xenografted glioblastoma cell lines (U87MG) were randomized to four experimental groups: (i) untreated, (ii) temozolomide alone, (iii) olaprib alone and, (iv) olaparib+temozolomide. Mice were treated daily for 4 weeks and monitored for tumor growth, and survival. However, the addition of olaparib had no impact on the efficacy of temozolomide. The combination of PARP inhibitor olaparib with temozolomide could be an effective therapeutic approach for treatment of glioblastoma regardless of MGMT promotor methylation status, although the efficacy still should be evaluated by in vivo and clinical studies." @default.
- W3113016627 created "2020-12-21" @default.
- W3113016627 creator A5009941217 @default.
- W3113016627 creator A5011170222 @default.
- W3113016627 creator A5017531565 @default.
- W3113016627 creator A5033093147 @default.
- W3113016627 creator A5043960157 @default.
- W3113016627 creator A5079052740 @default.
- W3113016627 date "2020-11-01" @default.
- W3113016627 modified "2023-09-26" @default.
- W3113016627 title "DDRE-23. THE COMBINATION PARP INHIBITOR OLAPARIB WITH TEMOZOLOMIDE IN AN EXPERIMENTAL GLIOBLASTOMA MODEL" @default.
- W3113016627 doi "https://doi.org/10.1093/neuonc/noaa215.268" @default.
- W3113016627 hasPublicationYear "2020" @default.
- W3113016627 type Work @default.
- W3113016627 sameAs 3113016627 @default.
- W3113016627 citedByCount "0" @default.
- W3113016627 crossrefType "journal-article" @default.
- W3113016627 hasAuthorship W3113016627A5009941217 @default.
- W3113016627 hasAuthorship W3113016627A5011170222 @default.
- W3113016627 hasAuthorship W3113016627A5017531565 @default.
- W3113016627 hasAuthorship W3113016627A5033093147 @default.
- W3113016627 hasAuthorship W3113016627A5043960157 @default.
- W3113016627 hasAuthorship W3113016627A5079052740 @default.
- W3113016627 hasBestOaLocation W31130166271 @default.
- W3113016627 hasConcept C104317684 @default.
- W3113016627 hasConcept C150903083 @default.
- W3113016627 hasConcept C181199279 @default.
- W3113016627 hasConcept C182979987 @default.
- W3113016627 hasConcept C185592680 @default.
- W3113016627 hasConcept C207001950 @default.
- W3113016627 hasConcept C2777389519 @default.
- W3113016627 hasConcept C2778227246 @default.
- W3113016627 hasConcept C2779138821 @default.
- W3113016627 hasConcept C2779527866 @default.
- W3113016627 hasConcept C2779962180 @default.
- W3113016627 hasConcept C33288867 @default.
- W3113016627 hasConcept C502942594 @default.
- W3113016627 hasConcept C55493867 @default.
- W3113016627 hasConcept C71924100 @default.
- W3113016627 hasConcept C82381507 @default.
- W3113016627 hasConcept C86803240 @default.
- W3113016627 hasConcept C91965660 @default.
- W3113016627 hasConcept C98274493 @default.
- W3113016627 hasConceptScore W3113016627C104317684 @default.
- W3113016627 hasConceptScore W3113016627C150903083 @default.
- W3113016627 hasConceptScore W3113016627C181199279 @default.
- W3113016627 hasConceptScore W3113016627C182979987 @default.
- W3113016627 hasConceptScore W3113016627C185592680 @default.
- W3113016627 hasConceptScore W3113016627C207001950 @default.
- W3113016627 hasConceptScore W3113016627C2777389519 @default.
- W3113016627 hasConceptScore W3113016627C2778227246 @default.
- W3113016627 hasConceptScore W3113016627C2779138821 @default.
- W3113016627 hasConceptScore W3113016627C2779527866 @default.
- W3113016627 hasConceptScore W3113016627C2779962180 @default.
- W3113016627 hasConceptScore W3113016627C33288867 @default.
- W3113016627 hasConceptScore W3113016627C502942594 @default.
- W3113016627 hasConceptScore W3113016627C55493867 @default.
- W3113016627 hasConceptScore W3113016627C71924100 @default.
- W3113016627 hasConceptScore W3113016627C82381507 @default.
- W3113016627 hasConceptScore W3113016627C86803240 @default.
- W3113016627 hasConceptScore W3113016627C91965660 @default.
- W3113016627 hasConceptScore W3113016627C98274493 @default.
- W3113016627 hasIssue "Supplement_2" @default.
- W3113016627 hasLocation W31130166271 @default.
- W3113016627 hasLocation W31130166272 @default.
- W3113016627 hasLocation W31130166273 @default.
- W3113016627 hasOpenAccess W3113016627 @default.
- W3113016627 hasPrimaryLocation W31130166271 @default.
- W3113016627 hasRelatedWork W1876426852 @default.
- W3113016627 hasRelatedWork W2024800021 @default.
- W3113016627 hasRelatedWork W2741839613 @default.
- W3113016627 hasRelatedWork W2883697601 @default.
- W3113016627 hasRelatedWork W2950939271 @default.
- W3113016627 hasRelatedWork W2986241359 @default.
- W3113016627 hasRelatedWork W3036245422 @default.
- W3113016627 hasRelatedWork W3113016627 @default.
- W3113016627 hasRelatedWork W3119609126 @default.
- W3113016627 hasRelatedWork W3208048504 @default.
- W3113016627 hasVolume "22" @default.
- W3113016627 isParatext "false" @default.
- W3113016627 isRetracted "false" @default.
- W3113016627 magId "3113016627" @default.
- W3113016627 workType "article" @default.